When was Electra Therapeutics founded?

Electra Therapeutics was founded in 2018 and raised its 1st funding round 4 years after it was founded.

Where is Electra Therapeutics located?

Electra Therapeutics is headquartered in San Francisco, United States.

Who is the current CEO of Electra Therapeutics?

Adam Rosenthal of Electra Therapeutics. They have also founded 2 companies.

How many employees does Electra Therapeutics have?

As of Mar 31, 2026, the latest employee count at Electra Therapeutics is 37.

Is Electra Therapeutics a funded company?

Electra Therapeutics is a funded company, having raised a total of $267M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Feb 17, 2022.

When was the latest funding round of Electra Therapeutics?

Electra Therapeutics' latest funding was a $***** Series C round on Oct 15, 2025, with participation from 13 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $2.05B in funding in 2026 to date.

Where does Electra Therapeutics rank among its competitors?

Electra Therapeutics ranks 104th amongst 3495 active competitors, of which 1203 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Electra Therapeutics, which secured $183M in Oct, 2025.

Who are the top competitors of Electra Therapeutics?

Electra Therapeutics' top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Electra Therapeutics secured the most recent funding round in October, 2025.

Electra Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Electra Therapeutics is a series C company based in San Francisco (United States), founded in 2018 by Adam Rosenthal. It operates as a Developer of therapies for immunological diseases and cancer. Electra Therapeutics has raised $267M in funding from investors like Orbimed, Nextech Invest and EQT. The company has 3495 active competitors, including 1203 funded and 840 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.

Company Details

Developer of therapies for immunological diseases and cancer. The company focuses on the development of therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. The company's lead product ELA026, is a monoclonal antibody to treat secondary hemophagocytic lymphohistiocytosis (sHLH).

Website: electra-therapeutics.com
Email ID: *****@electra-therapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Series C

Total Funding

$267M in 3 rounds

Latest Funding Round

Series C, Oct 15, 2025, $*****

Investors

Orbimed & 14 more

Ranked

104^th among 3495 active competitors

Employee Count

37 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3351 more

View Electra Therapeutics' full profile

Electra Therapeutics has raised a total funding of $267M over 3 rounds. Its first funding round was on Feb 17, 2022. Its latest funding round was a Series C round on Oct 15, 2025 for $*****. 13 investors participated in its latest round. Electra Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of Electra Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 15, 2025	2415190	Series C	7824753	2352491	4432727	2381989
Dec 22, 2023	6974860	Series B	7343231	6389788	2360527	2361168
Feb 17, 2022	9377507	Series B	1305309	1001964	Westlake Village Biopartners & 1 more	Redmile Group & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Electra Therapeutics's funding rounds and investors

The founders of Electra Therapeutics is Adam Rosenthal. Adam Rosenthal is the CEO of Electra Therapeutics.

Here are the details of Electra Therapeutics' key team members:

Adam Rosenthal: Co-Founder & CEO of Electra Therapeutics and founder of 1 other company.
Contact Info: 1 email address

View details of Electra Therapeutics's Founder profiles and Board Members

Electra Therapeutics' employee count trend

Electra Therapeutics has 37 employees as of Mar 26. Here is Electra Therapeutics's employee count trend over the years:

Employee count trend for Electra Therapeutics

Uncover Electra Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Electra Therapeutics include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Electra Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
9th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
104th	Electra Therapeutics 2018, San Francisco (United States), Series C	Developer of therapies for immunological diseases and cancer	$267M	RA Capital Management, Redmile Group & 13 others	63/100